Advertisement

Search Results

Advertisement



Your search for The ASCO ,The ASCO matches 20586 pages

Showing 6601 - 6650


Expert Point of View: Craig Hofmeister, MD, MPH

“The IKEMA trial is based on the interest of adding a CD38 naked antibody to a carfilzomib-plus-dexamethasone skeleton, a protocol nearly identical to the recently presented CANDOR trial,” said Craig Hofmeister MD, MPH, Associate Professor of Hematology and Oncology at the Winship Cancer Institute...

lymphoma

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better...

breast cancer
genomics/genetics

Presence of ctDNA and CTCs and Prediction of Disease Recurrence in Patients With Triple-Negative Breast Cancer

In a preplanned secondary analysis of the BRE12-158 trial published in JAMA Oncology, Milan Radovich, PhD, and colleagues found that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women who have received neoadjuvant treatment for stage I, II, or...

colorectal cancer

Common Hypertension Medications May Also Reduce Risk of Colorectal Cancer

Medications commonly prescribed to treat high blood pressure may also reduce the risk of colorectal cancer, according to new research published by Cheung et al in the journal Hypertension. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) are often prescribed...

cost of care

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration ...

cost of care
health-care policy

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of...

health-care policy
genomics/genetics

Trends in Policy Coverage for ctDNA Testing

New research published by Douglas et al in JNCCN—Journal of the National Comprehensive Cancer Network examined coverage trends for circulating tumor DNA (ctDNA) testing, also known as liquid biopsy. In the first-ever study to analyze insurance coverage for ctDNA-based panel tests, researchers found ...

issues in oncology

American Cancer Society Updates Guideline for HPV Vaccination

The American Cancer Society (ACS) has updated its guideline for human papillomavirus (HPV) vaccination, adapting a 2019 update from the Federal Advisory Committee on Immunization Practices (ACIP). The ACS first issued a guideline for routine use of the HPV vaccine in 2007, with an update issued in...

head and neck cancer

Facing Death and Appreciating Life

I have had to come to terms with my own mortality three times in my life and I’m only 46. When I was 17, I was diagnosed with end-stage renal disease and experienced renal failure 2 years later. I underwent my first kidney transplant at 21, just before starting medical school. Finally, I thought my ...

Expect Questions About Minimally Invasive Surgery for Early-Stage Cervical Cancer

A recent systematic review and meta-analysis found that women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of disease recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy.1 “These...

gynecologic cancers

Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer

Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...

Patricia S. Steeg, PhD, Receives Women in Cancer Research Charlotte Friend Lectureship

The American Association for Cancer Research (AACR) has honored Patricia S. Steeg, PhD, with its 2020 Women in Cancer Research Charlotte Friend Memorial Lectureship. Dr. Steeg, Co-Director of the Office of Translational Resources and Associate Director of the Center for Cancer Research at the...

Christopher I. Amos, PhD, Receives Award for Research Excellence in Cancer Epidemiology and Prevention

The American Association for Cancer Research (AACR) is honoring Christopher I. Amos, PhD, with the 2020 AACR–American Cancer Society (ACS) Award for Research Excellence in Cancer Epidemiology and Prevention. Dr. Amos, the Selzman Endowed Professor, Director of the Institute for Clinical and...

Benjamin F. Cravatt, PhD, Receives Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research (AACR) is honoring Benjamin F. Cravatt, PhD, with the 2020 AACR Award for Outstanding Achievement in Chemistry in Cancer Research. Dr. Cravatt, Professor at the Skaggs Institute for Chemical Biology and the Gilula Chair of Chemical Biology for the...

Charles L. Sawyers, MD, FAACR, Voted AACR Academy President-Elect for 2020–2021

The Fellows of the American Association for Cancer Research (AACR) Academy have chosen Charles L. Sawyers, MD, FAACR, as President-Elect for 2020–2021. Dr. Sawyers will assume the presidency during the 2021 AACR Annual Meeting. Dr. Sawyers holds the Marie-Josée and Henry R. Kravis Chair in Human...

Neil Spector, MD, Physician-Scientist, Mentor, Author, Dies at 63

Neil Spector, MD, a physician-scientist, translational research leader, and oncology mentor died on June 14, 2020. He was 63. Dr. Spector was the Sandra Coates Associate Professor in the Department of Medicine, Associate Professor of Pharmacology and Cancer Biology, and a member of the Duke Cancer ...

Beth Levine, MD, Renowned Doctor and Researcher in the Field of Autophagy, Dies at 60

Beth Levine, MD, Professor of Internal Medicine and Microbiology, Director of the Center for Autophagy Research, and Charles Cameron Sprague Distinguished Chair in Biomedical Sciences at The University of Texas Southwestern Medical Center (UT Southwestern), and an investigator at the Howard Hughes ...

Oscar Colegio,MD, PhD, Expert on Skin Cancers Linked to Immunodeficiencies, Dies at 47

Oscar Colegio, MD, PhD, the Lawrence P. & Joan Castellani Family Endowed Chair in Dermatology at Roswell Park Comprehensive Cancer Center, Buffalo, New York, died unexpectedly on June 13, 2020, at a family residence in Connecticut. He was 47. Dr. Colegio had relocated to Buffalo when he was...

New James Cancer Diagnostic Center to Expedite Access to Diagnostic Testing

A recently opened center at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) gives patients direct, expedited access to diagnostic testing for cancer. The goal, said Chief Medical Officer David Cohn, MD,...

The Piano

The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Cancer Genome Atlas Founding Members and Current Project Team Awarded 2020 AACR Team Science Awards

During its recent Virtual Annual Meeting II, the American Association for Cancer Research (AACR) presented its 2020 Team Science Awards to the founding members and the current project team associated with The Cancer Genome Atlas (TCGA). TCGA began in 2006 as a joint effort between the National...

Kunle Odunsi, MD, PhD, FRCOG, FACOG, Elected At-Large Director of SITC Board of Directors

Elected by a body of fellow immunotherapy researchers from across the globe, Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, has been named At-Large Director of the Society for Immunotherapy of Cancer (SITC) Board of Directors. Dr. Odunsi will begin his ...

lung cancer

Do Not Rush to High-Dose Twice-Daily Radiation for Limited Small Cell Lung Cancer

Bjørn Henning Gronberg, MD, PhD, presented a paper at the ASCO20 Virtual Scientific Program reporting astounding positive results favoring higher-dose, twice-daily radiation therapy in limited-stage small cell lung cancer.1 This was a phase II study (large for phase II but small for phase III)...

integrative oncology

Elderberry

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on...

prostate cancer
genomics/genetics

New Recommendations Offer Guidance for Clinicians and Patients on Genetic Testing for Prostate Cancer

An international panel of experts led by researchers and thought leaders at the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) and the Department of Urology at Jefferson have published the first multidisciplinary, consensus-driven, prostate cancer genetic implementation framework for the...

hepatobiliary cancer
immunotherapy

IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?

In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...

covid-19

FDA Collaborating on Use of Real-World Data to Inform COVID-19 Response Effort

On June 18, 2020, the U.S. Food and Drug Administration (FDA) took an additional step in harnessing real-world data to help inform the agency’s overall response to the COVID-19 public health emergency. The FDA announced its participation in the COVID-19 Diagnostics Evidence Accelerator, a...

palliative care

A Palliative Care Specialist Explores What It Means to Live and Die With Dignity and Purpose

Palliative care’s road to acceptance as standard-of-care practice has been a remarkably unsmooth one, given its core mission: improving the quality of life of patients and their families by relieving the pain, symptoms, and stress of a serious or life-limiting illness. A person’s relationship with...

AACR Recognizes Achievements of Three Cancer Researchers

The American Association for Cancer Research (AACR) is honoring three clinical cancer researchers for their outstanding achievements. Jedd D. Wolchok, MD, PhD, FASCO, will receive the 2020 AACR–Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research. Lisa A. Newman, MD,...

Jessica Karen Wong, MD, MEng, Joins Radiation Oncology Department at Fox Chase

Fox Chase Cancer Center announced that Jessica Karen Wong, MD, MEng, recently joined the Department of Radiation Oncology as Assistant Professor in the academic clinician track. Dr. Wong completed her radiation oncology residency program at Fox Chase, where she served as Chief Resident in 2019 and...

bladder cancer
immunotherapy

Expert Point of View: Daniel Y. Heng, MD, MPH, and Toni K. Choueiri, MD

Study discussant Daniel Y. Heng, MD, MPH, a medical oncologist at Tom Baker Cancer Centre, University of Calgary, Canada, called the negative trial results important. IMvigor010 randomly assigned patients with high-risk muscle-invasive urothelial carcinoma to adjuvant atezolizumab or observation...

bladder cancer
immunotherapy

Adjuvant Atezolizumab Fails to Meet Primary Study Endpoint in High-Risk Bladder Cancer

Adjuvant atezolizumab, a PD-L1–blocking antibody, failed to meet the primary endpoint of disease-free survival in patients at high risk of recurrence of muscle-invasive bladder cancer compared with observation alone, according to the primary analysis of the IMvigor010 trial reported during the...

breast cancer
immunotherapy

Roundup of High-Impact Studies in Early Breast Cancer

Clinicians interested in breast cancer who logged into the ASCO20 Virtual Scientific Program were greeted with an abundance of high-impact presentations. The ASCO Post has reported on several studies in depth elsewhere, but here we offer our readers a roundup of several important studies in early...

geriatric oncology

Geriatric Assessment: What Are You Waiting For?

The ASCO20 Virtual Scientific Program was the forum for an unusual but profoundly important event in oncology. Four studies that should be practice-changing were presented.1-4 These studies provided irrefutable evidence that we can improve the quality of life of older patients by reducing toxicity. ...

multiple myeloma
immunotherapy

Expert Point of View: Philip McCarthy, MD

Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York, found the results of the DREAMM-6 study to be “exciting and promising.” He commented: “The overall response...

AACR Recognizes New 2019–2020 Research Grantees

The American Association for Cancer Research (AACR) has announced its newest class of grant recipients. Fellowships The 2019 Anna D. Barker Fellowship in Basic Cancer Research was awarded to Chaoyun Pan, PhD, of Emory University, Atlanta, and Conghui Yao, PhD, of Harvard Medical School, Cambridge....

lung cancer

Lung Cancer Research Foundation Names Trudy Oliver, PhD, to Its Scientific Advisory Board

The Lung Cancer Research Foundation (LCRF) recently announced that Trudy Oliver, PhD, has joined its Scientific Advisory Board. Dr. Oliver is Associate Professor of Oncological Sciences at the University of Utah’s Huntsman Cancer Institute (HCI), where she has served since 2011, and is an HCI...

lung cancer
immunotherapy

Phase II Study Evaluates Chemotherapy and Immunotherapy in Patients With Malignant Pleural Mesothelioma

Data from the phase II PrE0505 multicenter trial showed that adding durvalumab, an immune checkpoint antibody targeting programmed cell death ligand 1 (PD-L1), to the combination of cisplatin and pemetrexed chemotherapy improved outcomes in previously untreated patients with unresectable malignant...

Her Grandfather’s Medical Practice Inspired Nathalie LeVasseur, MD, BSc, FRCPC, to Improve the Lives of Women With Breast Cancer

At the 2018 ASCO Annual Meeting, Nathalie LeVasseur, MD, BSc, FRCPC, received the Annual Meeting Merit Award for a project titled, “Whole-Genome Sequencing in Metastatic Breast Cancer: Lessons Learned From the BC Cancer Personalized Oncogenomics Program.” Along with her clinical work, Dr....

A New Website Offers Support for Adolescent and Young Adults With Cancer During the COVID-19 Pandemic

Although the full impact of the COVID-19 pandemic on patients with cancer is still being evaluated, data from several studies show that in comparison with people who do not have cancer, those who do generally experience a higher risk of severe events including admittance to the intensive care unit, ...

pain management

Understanding the Underlying Mechanisms of Pain in Patients With Cancer

Pain is among the most difficult medical issues for oncologists to confront, said Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego, during his keynote address at the 2019 Supportive Care in Oncology Symposium. Failure to adequately manage...

issues in oncology

Improving the Quality of Care and Research for Patients With Cancer and the Ethics Behind Its Delivery

With the rapid expansion of scientific advances, the intersection of ethics and the delivery of cancer care becomes ever more complicated. To shed light on some of the challenging ethical issues faced by today’s busy oncology practitioners, The ASCO Post spoke with Rebecca D. Pentz, PhD, Professor ...

Donor Spotlight: GO2 Foundation for Lung Cancer Unifies to Drive Change

In 2019, the GO2 Foundation for Lung Cancer was born from the merger of the Bonnie J. Addario Lung Cancer Foundation and the Lung Cancer Alliance. The marriage of two lung cancer advocacy groups raises the profile of each group’s work and combines considerable resources to combat lung cancer. The...

Conquer Cancer Grants More Than $8 Million to Cancer Research

Conquer Cancer, the ASCO Foundation, announced its 2020 grant and award recipients in conjunction with the 2020 ASCO Virtual Scientific Program. The awards will support researchers with projects spanning many areas in cancer care, including immunotherapy, lung and breast cancers, and palliative...

covid-19

ASCO COVID-19 Registry: Acceptable for MIPS Improvement Activity

ASCO’s Survey on COVID-19 in Oncology Registry (ASCO Registry) is an acceptable clinical trial registry for the attestation of the high-weighted practice Improvement Activity, “COVID-19 Clinical Trials Related to the Emergency Response & Preparedness,” under the Centers for Medicare &...

covid-19

Guidance Available on Telemedicine Coverage During COVID-19 Pandemic

Effective for services starting March 1, 2020, and for the duration of the COVID-19 emergency, the Centers for Medicare & Medicaid Services (CMS) will reimburse for telehealth services for all beneficiaries. To help explain this and other changes to telehealth coverage related to the pandemic,...

covid-19

2020 ASCO Presidential Address Focuses on ‘Unite and Conquer: Accelerating Progress Together’

The world is grappling with a pandemic and we are all adjusting to a new reality. Fewer handshakes, more masks. Fewer hugs, more fear. COVID-19 has tested us, challenged us, changed us. It’s changed the way we look, the way we work, the way we socialize. It’s changed us, but it can’t stop us. It...

Glenn D. Steele, Jr, MD, PhD, Named Chair of City of Hope Board of Directors

Health-care innovator and leader Glenn D. Steele Jr, MD, PhD, has been elected Board Chair at City of Hope. Dr. Steele joined the City of Hope Board of Directors in 2016 and was Chair of the Executive Compensation and Governance Committee from 2018 to 2020. “City of Hope has benefited from...

immunotherapy

New NCCN Guidelines Offer Patients Help in Recognizing Side Effects From Immunotherapy

The National Comprehensive Cancer Network (NCCN) recently announced the publication of “NCCN Guidelines for Patients: Immunotherapy Side Effects—Immune Checkpoint Inhibitors.” These new guidelines are designed to educate patients and to help them recognize immune side effects so effective...

ASCO Opens Search for Chief Medical Officer: Express Interest by August 21, 2020

ASCO is conducting an open search for the position of Chief Medical Officer and Executive Vice President, as current Chief Medical Officer, Richard L. Schilsky, MD, FACP, FSCT, FASCO, prepares to retire in February 2021. ASCO’s Chief Medical Officer applies his/her medical and scientific knowledge ...

Advertisement

Advertisement




Advertisement